Prior studies have also linked elevated VEGF-A levels with worse outcomes in respiratory diseases, such as ARDS, which shares some pathophysiological features with severe COVID-19, including hypoxia-induced vascular leakage and inflammation [42, 43]. Here, VEGFA is linked to respiratory system disorder.